HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

BNTX — BioNTech SE

BNTX (BioNTech SE) stock: $87.40, $21.96B market cap, $8.64B cash, $13.32B EV, $22.03B fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

We were founded and incorporated on June 2, 2008 as Petersberg 91, V AG, a German stock corporation (Aktiengesellschaft). We changed our name to BioNTech AG on December 11, 2008. On March 8, 2019, we converted to a European stock corporation (Societas Europaea, or SE) under the laws of Germany and the European Union called BioNTech SE.

Source: 20-F FY2025 via SEC EDGAR

Share price
$87.40
Market cap
$21,955.3M
Cash
$8,637.1M
Enterprise value
$13,318.1M

Balance sheet

Cash$8,637.1M
Debt$0.0M
Net cash$8,637.1M
Enterprise value$13,318.1M
Basic shares251.2M shares
Fully diluted shares252.1M shares
Fully diluted market cap$22,032.2M
Cash per share$34.38

Cash figures as of 2025-12-31. Database snapshot: 2026-11-11.

Share structure

Common
251.3M
Pre-funded warrants
0.0M
Options
0.1M
RSUs
0.6M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
252.1M

Cap table as of 2025-12-31.

Price history

Loading BNTX daily closes…

Loading price history…

Next catalyst

BNT113 · Est. Nov 11, 2026 · guidance midpoint · guided Now

Recently reported

DB-1303/BNT323 Phase 3 Positive · 2026-10-26
metastatic breast cancer
Primary: Progression-free survival (PFS) in the DYNASTY-Breast02 global Phase 3 trial (NCT06018337) of trastuzumab pamirtecan in HR+/HER2-low metastatic breast cancer — Met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (PFS) with trastuzumab pamirtecan compared to investigator's choice of chemotherapy (magnitude not disclosed in the release)
· 541 patients with HER2-low expression randomized 1:1 to trastuzumab pamirtecan or investigator's choice single-agent chemotherapy
· At this interim analysis for the secondary endpoint of overall survival (OS), data were not mature
· The companies said the available data suggest the potential benefit to patients would be limited in the current HR+/HER2-low metastatic breast cancer treatment landscape and that they will discuss the data and determine next steps
Safety: A higher rate of interstitial lung disease (ILD) was reported compared to prior trials, with most cases Grade 1 and 2 and severe and fatal events (Grade 3-5) in a small proportion of patients; otherwise consistent with prior trials, no new safety signals
Source release →
Pumitamig Phase 2 Mixed · 2026-10-25
Primary: Confirmed objective response rate (cORR) in the global Phase 2 ROSETTA Lung-107 trial (NCT06841055) of pumitamig in combination with docetaxel in metastatic NSCLC progressed on or after first-line immunotherapy plus chemotherapy — Among 30 efficacy-evaluable patients, pumitamig plus docetaxel showed a confirmed objective response rate (cORR) of 36.7% with a disease control rate (DCR) of 90.0%
· In the overall treated population (n=50), median progression-free survival (PFS) was 6.9 months (95% CI: 4.2 – not reached), with a six-month PFS rate of 63.3%
· Median time to response was 1.4 months
· cORR by PD-L1: 42.9% TPS < 1%; 33.3% TPS 1–49%; 40.0% TPS ≥ 50%
· cORR by histology: 57.1% squamous; 30.4% non-squamous, with DCRs above 80% in all subgroups
· July 10, 2026, data cut-off included 50 patients with a median follow-up of 12.2 weeks, and 33 patients remained on treatment
Safety: Pumitamig treatment-related adverse events (TRAEs) of any grade were reported in 52.0% of patients and grade ≥ 3 TRAEs in 18.0%, leading to treatment discontinuation in four (8.0%) patients; no pumitamig-related deaths or dose-limiting toxicities (DLTs)
Source release →
BNT113 Phase 2/3 Mixed · 2026-10-13
AHEAD-MERIT · unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer
Primary: Progression-free survival (one of dual primary endpoints, alongside overall survival, in the Phase 3 part of AHEAD-MERIT) — did not demonstrate a statistically significant improvement in PFS versus pembrolizumab alone
· Phase 2/3 AHEAD-MERIT (NCT04534205): BNT113 plus pembrolizumab vs pembrolizumab monotherapy, first-line, unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1
· Dual primary endpoints are progression-free survival and overall survival
· IDMC recommended the trial continue as planned to evaluate overall survival
· Under the pre-specified design, a statistically significant overall survival improvement would establish a positive trial outcome even though the PFS endpoint was not met
· BioNTech remains blinded to ongoing trial data
· No numeric PFS result was disclosed in the release
Safety: not disclosed
Source release →
gotistobart (BNT316/ONC-392) Phase 3 Positive · 2026-09-14
PRESERVE-003 · squamous non-small cell lung cancer progressed on prior immunotherapy and chemotherapy
Source release →
autogene cevumeran (BNT122) Phase 2 Negative · 2026-08-28
BNT122-01 · ctDNA-positive resected high-risk stage II/III colorectal cancer
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 718 stocks.
Subscribe to Compounding Ego